ReviewJournal of nanobiotechnology2026
Advances in nano-TCM for Alzheimer's disease: lipid-based carriers integrated with innovative delivery strategies.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by β-amyloid (Aβ) plaque deposition, tau hyperphosphorylation, neuroinflammation, and oxidative stress. However, current therapies remain largely symptomatic. Traditional Chinese Medicine (TCM)-derived monomers exhibit considerable anti-AD potential owing to their multitarget neuroprotective activities. However, their therapeutic translation is severely limited by poor stability, low bioavailability, and restricted brain delivery across the blood-brain barrier (BBB). This review summarizes the pathological basis of AD, the neuroprotective mechanisms of representative TCM-derived monomers, and the major BBB-related barriers that hinder effective brain delivery. Particular emphasis is placed on lipid-based nanocarriers, including exosomes, liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), as platforms for improving drug stability, BBB transport, and brain accumulation. We further highlight innovative delivery strategies that integrate ligand-mediated targeting with biomimetic modification, particularly cell membrane camouflage and exosome-inspired engineering. These approaches may confer immune evasion, prolonged circulation, enhanced biocompatibility, and improved lesion-oriented delivery. Finally, we discuss the challenges facing the clinical translation of lipid-based nanocarriers, including large-scale production, quality control, regulatory considerations, and long-term safety. Collectively, these lipid-based nanoplatforms provide a promising framework for advancing next-generation nano-TCM therapeutics for AD. Future progress will depend on optimized carrier design, rigorous mechanistic validation, comprehensive long-term safety assessment, and clinically relevant translational studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.